Biomarkers in Endometrial Cancer: Possible Clinical Applications (Review)

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Jul 12

PMID 22783413

Citations 23

Authors

Kouji Banno

Iori Kisu

Megumi Yanokura

Kosuke Tsuji

Kenta Masuda

Arisa Ueki

Yusuke Kobayashi

Wataru Yamagami

Hiroyuki Nomura

Eiichiro Tominaga

Nobuyuki Susumu

Daisuke Aoki

Affiliations

Soon will be listed here.

Abstract

The number of cases of endometrial cancer has shown a tendency to increase in recent years. Endometrial cancer originates from the endometrium and is classified, based on the development mechanism, into types 1 and 2, which are responsive and non-responsive to estrogen, respectively, and have significantly different gene expression profiles. Studies of genes with abnormal expression in endometrial cancer have identified multiple oncogenes, tumor suppressors, mismatch repair genes, apoptosis-associated genes, levels of hormone receptors and DNA ploidy and aneuploidy as biomarkers of endometrial cancer. The use of these molecules and genes may facilitate accurate diagnosis and prognostic prediction and contribute to individualized treatment. Trials of drugs which target these biomarkers and searches for new biomarkers using cDNA microarrays and RT-qPCR are ongoing and it is likely that these findings can be translated to clinical use.

Citing Articles

Functional Analysis of RE1 Silencing Transcription Factor as a Putative Tumor Suppressor in Human Endometrial Cancer.

Abedin Y, Minchella P, Peterson R, Gonnella F, Graham A, Cook I Int J Mol Sci. 2024; 25(17).

PMID: 39273639 PMC: 11395688. DOI: 10.3390/ijms25179693.

Integrating proteomics and explainable artificial intelligence: a comprehensive analysis of protein biomarkers for endometrial cancer diagnosis and prognosis.

Yasar S, Yagin F, Melekoglu R, Ardigo L Front Mol Biosci. 2024; 11:1389325.

PMID: 38894711 PMC: 11184912. DOI: 10.3389/fmolb.2024.1389325.

Identification of Endometrial Cancer-Specific microRNA Biomarkers in Endometrial Fluid.

Yang J, Barkley J, Bhattarai B, Firouzi K, Monk B, Coonrod D Int J Mol Sci. 2023; 24(10).

PMID: 37240034 PMC: 10218319. DOI: 10.3390/ijms24108683.

lncRNA XIST/miR‑129‑2‑3p axis targets CCP110 to regulate the proliferation, invasion and migration of endometrial cancer cells.

Chen S, Liang Y, Shen Y, Wang X Exp Ther Med. 2023; 25(4):159.

PMID: 36911384 PMC: 9996364. DOI: 10.3892/etm.2023.11858.

Gel-Based Proteomic Identification of Suprabasin as a Potential New Candidate Biomarker in Endometrial Cancer.

Celsi F, Monasta L, Arrigoni G, Battisti I, Licastro D, Aloisio M Int J Mol Sci. 2022; 23(4).

PMID: 35216190 PMC: 8880426. DOI: 10.3390/ijms23042076.

References

Berchuck A, Rodriguez G, Kinney R, Soper J, Dodge R, Clarke-Pearson D . Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol. 1991; 164(1 Pt 1):15-21. DOI: 10.1016/0002-9378(91)90615-x. View

Horree N, van Diest P, Sie-Go D, Heintz A . The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol. 2007; 38(8):1232-8. DOI: 10.1016/j.humpath.2007.01.008. View

Risinger J, Dent G, McLachlan J, Tsao M, Senterman M, Boyd J . p53 gene mutations in human endometrial carcinoma. Mol Carcinog. 1992; 5(4):250-3. DOI: 10.1002/mc.2940050403. View

Prat J . Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004; 35(6):649-62. DOI: 10.1016/j.humpath.2004.02.007. View

Nuovo G, Plaia T, Belinsky S, Baylin S, Herman J . In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A. 1999; 96(22):12754-9. PMC: 23084. DOI: 10.1073/pnas.96.22.12754. View

McDonnell D, Norris J . Connections and regulation of the human estrogen receptor. Science. 2002; 296(5573):1642-4. DOI: 10.1126/science.1071884. View

Colas E, Perez C, Cabrera S, Pedrola N, Monge M, Castellvi J . Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer. 2011; 129(10):2435-44. DOI: 10.1002/ijc.25901. View

Sakuragi N, Salah-Eldin A, Watari H, Itoh T, Inoue S, Moriuchi T . Bax, Bcl-2, and p53 expression in endometrial cancer. Gynecol Oncol. 2002; 86(3):288-96. DOI: 10.1006/gyno.2002.6742. View

Soong R, Knowles S, Williams K, Hammond I, Wysocki S, Iacopetta B . Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer. 1996; 74(4):562-7. PMC: 2074673. DOI: 10.1038/bjc.1996.401. View

10.

Salvesen H, Iversen O, Akslen L . Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol. 1999; 17(5):1382-90. DOI: 10.1200/JCO.1999.17.5.1382. View

11.

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I . Endometrial cancer. Lancet. 2005; 366(9484):491-505. DOI: 10.1016/S0140-6736(05)67063-8. View

12.

van der Putten H, Baak J, Koenders T, Kurver P, Stolk H, STOLTE L . Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer. 1989; 63(7):1378-87. DOI: 10.1002/1097-0142(19890401)63:7<1378::aid-cncr2820630724>3.0.co;2-q. View

13.

Salvesen H, Macdonald N, Ryan A, Jacobs I, Lynch E, Akslen L . PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer. 2001; 91(1):22-6. DOI: 10.1002/1097-0215(20010101)91:1<22::aid-ijc1002>3.0.co;2-s. View

14.

Dutt A, Salvesen H, Chen T, Ramos A, Onofrio R, Hatton C . Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008; 105(25):8713-7. PMC: 2438391. DOI: 10.1073/pnas.0803379105. View

15.

Lax S, Kendall B, Tashiro H, Slebos R, Hedrick L . The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000; 88(4):814-24. View

16.

Yamazawa K, Seki K, Matsui H, Kihara M, Sekiya S . Prognostic factors in young women with endometrial carcinoma: a report of 20 cases and review of literature. Int J Gynecol Cancer. 2001; 10(3):212-222. DOI: 10.1046/j.1525-1438.2000.010003212.x. View

17.

Catasus L, Machin P, Matias-Guiu X, Prat J . Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol. 1998; 29(10):1160-4. DOI: 10.1016/s0046-8177(98)90430-0. View

18.

Caduff R, Johnston C, Frank T . Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol. 1995; 146(1):182-8. PMC: 1870768. View

19.

Soong R, Robbins P, Dix B, Grieu F, Lim B, Knowles S . Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol. 1996; 27(10):1050-5. DOI: 10.1016/s0046-8177(96)90282-8. View

20.

Prat J, Gallardo A, Cuatrecasas M, Catasus L . Endometrial carcinoma: pathology and genetics. Pathology. 2007; 39(1):72-87. DOI: 10.1080/00313020601136153. View